List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7286575/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Diabetes Care, 2012, 35, 1364-1379.	8.6	3,077
2	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38, 140-149.	8.6	2,326
3	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2018, 41, 2669-2701.	8.6	2,190
4	Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2012, 55, 1577-1596.	6.3	1,718
5	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	13.7	1,179
6	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2018, 61, 2461-2498.	6.3	1,002
7	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2020, 43, 487-493.	8.6	846
8	Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Annals of Internal Medicine, 2013, 159, 262.	3.9	749
9	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2015, 58, 429-442.	6.3	598
10	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2020, 63, 221-228.	6.3	368
11	Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ: British Medical Journal, 2012, 344, e1369-e1369.	2.3	356
12	Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ: British Medical Journal, 2018, 361, k1310.	2.3	294
13	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 2016, 374, 1092-1094.	27.0	208
14	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism: Clinical and Experimental, 2017, 71, 17-32.	3.4	208
15	Comparative Effectiveness of Clucose-Lowering Drugs for Type 2 Diabetes. Annals of Internal Medicine, 2020, 173, 278-286.	3.9	182
16	Preferred reporting items for overviews of systematic reviews including harms checklist: a pilot tool to be used for balanced reporting of benefits and harms. Journal of Clinical Epidemiology, 2018, 93, 9-24.	5.0	177
17	Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2014, 16, 984-993.	4.4	176
18	Pharmacologic Interventions for Painful Diabetic Neuropathy. Annals of Internal Medicine, 2014, 161, 639.	3.9	148

APOSTOLOS TSAPAS

#	Article	IF	CITATIONS
19	Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379. Diabetes Care, 2013, 36, 490-490.	8.6	130
20	A systematic review and meta-analysis of tests to predict wound healing in diabetic foot. Journal of Vascular Surgery, 2016, 63, 29S-36S.e2.	1.1	116
21	Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Therapeutic Advances in Drug Safety, 2014, 5, 138-146.	2.4	96
22	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia, 2022, 65, 1251-1261.	6.3	93
23	A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome. Journal of Vascular Surgery, 2016, 63, 22S-28S.e2.	1.1	92
24	Performance of Baveno VI and Expanded Baveno VI Criteria for Excluding High-Risk Varices in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2019, 17, 1744-1755.e11.	4.4	84
25	Comparative efficacy of glucoseâ€lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2116-2124.	4.4	79
26	A systematic review and meta-analysis of adjunctive therapies in diabetic foot ulcers. Journal of Vascular Surgery, 2016, 63, 46S-58S.e2.	1.1	71
27	Semaglutide for type 2 diabetes mellitus: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2018, 20, 2255-2263.	4.4	71
28	Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease. Journal of Hypertension, 2019, 37, 2307-2324.	0.5	66
29	Diagnostic Accuracy of Fecal Immunochemical Test in Patients at Increased Risk for Colorectal Cancer. JAMA Internal Medicine, 2017, 177, 1110.	5.1	63
30	A systematic review and meta-analysis of off-loading methods for diabetic foot ulcers. Journal of Vascular Surgery, 2016, 63, 59S-68S.e2.	1.1	62
31	Efficacy and safety of onceâ€weekly glucagonâ€like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2015, 17, 1065-1074.	4.4	61
32	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2021, 174, 108737.	2.8	61
33	Basing information on comprehensive, critically appraised, and up-to-date syntheses of the scientific evidence: a quality dimension of the International Patient Decision Aid Standards. BMC Medical Informatics and Decision Making, 2013, 13, S5.	3.0	60
34	A systematic review and meta-analysis of débridement methods for chronic diabetic foot ulcers. Journal of Vascular Surgery, 2016, 63, 37S-45S.e2.	1.1	59
35	Common Variants in <i>FTO, MC4R, TMEM18, PRL, AIF1</i> , and <i>PCSK1</i> Show Evidence of Association With Adult Obesity in the Greek Population. Obesity, 2012, 20, 389-395.	3.0	56
36	Oral semaglutide for type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 335-345.	4.4	54

#	Article	IF	CITATIONS
37	Methods for depicting overlap in overviews of systematic reviews: An introduction to static tabular and graphical displays. Journal of Clinical Epidemiology, 2021, 132, 34-45.	5.0	52
38	Female fertility and colorectal cancer. International Journal of Colorectal Disease, 2008, 23, 735-743.	2.2	49
39	Accuracy of Magnetic Resonance Imaging in Diagnosis of Liver Iron Overload: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2015, 13, 55-63.e5.	4.4	49
40	N of 1 trials in diabetes: making individual therapeutic decisions. Diabetologia, 2008, 51, 921-925.	6.3	46
41	Prevention of orthodontic enamel demineralization: A systematic review with metaâ€analyses. Orthodontics and Craniofacial Research, 2019, 22, 225-235.	2.8	45
42	Glucagonâ€like peptideâ€1 receptor agonists and sodiumâ€glucose coâ€transporterâ€2 inhibitors as combination therapy for type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 1857-1868.	4.4	44
43	The effect of SCLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus. Journal of Hypertension, 2019, 37, 1334-1343.	0.5	43
44	Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine, 2016, 52, 458-480.	2.3	42
45	Systematic review with network metaâ€analysis: the impact of medical interventions for moderateâ€toâ€severe ulcerative colitis on healthâ€related quality of life. Alimentary Pharmacology and Therapeutics, 2018, 48, 1174-1185.	3.7	41
46	Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. Diabetes and Vascular Disease Research, 2008, 5, 216-218.	2.0	40
47	The Protective Role of the Mediterranean Diet on the Prevalence of Metabolic Syndrome in a Population of Greek Obese Subjects. Journal of the American College of Nutrition, 2010, 29, 41-45.	1.8	38
48	Accuracy of the Neuropad Test for the Diagnosis of Distal Symmetric Polyneuropathy in Type 2 Diabetes. Diabetes Care, 2011, 34, 1378-1382.	8.6	38
49	Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes. Annals of Internal Medicine, 2018, 169, 165.	3.9	38
50	Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Journal of Hypertension, 2021, 39, 749-758.	0.5	38
51	Glycaemic Control is Correlated with Well-Being Index (WHO-5) in Subjects with Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2010, 118, 364-367.	1.2	36
52	Guidelines for Medical Nutrition Therapy inÂGestational Diabetes Mellitus: Systematic Review and Critical Appraisal. Journal of the Academy of Nutrition and Dietetics, 2019, 119, 1320-1339.	0.8	36
53	Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece. Clinical Drug Investigation, 2018, 38, 417-426.	2.2	34
54	Glucagonâ€like peptideâ€1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2019, 21, 188-193.	4.4	33

#	Article	IF	CITATIONS
55	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Spectrum, 2012, 25, 154-171.	1.0	28
56	A simple plaster for screening for diabetic neuropathy: A diagnostic test accuracy systematic review and meta-analysis. Metabolism: Clinical and Experimental, 2014, 63, 584-592.	3.4	27
57	Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism, 2015, 6, 61-67.	3.2	26
58	Omega-3 supplementation and cardiovascular disease: formulation-based systematic review and meta-analysis with trial sequential analysis. Heart, 2021, 107, 150-158.	2.9	25
59	Systematic reviews supporting practice guideline recommendations lack protection against bias. Journal of Clinical Epidemiology, 2013, 66, 633-638.	5.0	23
60	Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, doubleâ€blind, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 517-524.	4.4	23
61	Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition. Hemoglobin, 2018, 42, 339-341.	0.8	22
62	Systematic reviews with language restrictions and no author contact have lower overall credibility: a methodology study. Clinical Epidemiology, 2015, 7, 243.	3.0	21
63	Enhanced laminin carbonylation by monocytes in diabetes mellitus. Clinical Biochemistry, 2007, 40, 671-679.	1.9	20
64	Gestational diabetes mellitus: why screen and how to diagnose. Hippokratia, 2010, 14, 151-4.	0.3	20
65	Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Expert Opinion on Pharmacotherapy, 2017, 18, 843-851.	1.8	19
66	Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Annals of Gastroenterology, 2018, 31, 572-582.	0.6	19
67	Sotagliflozin for patients with type <scp>2</scp> diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 106-114.	4.4	19
68	Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial. BMJ Open, 2016, 6, e012185.	1.9	18
69	Ultraâ€rapidâ€acting insulins for adults with diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 2395-2401.	4.4	18
70	Intravenous Magnesium Sulfate in Acute Stroke. Stroke, 2019, 50, 931-938.	2.0	17
71	Comparative efficacy and safety of glucoseâ€lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 822-831.	4.4	17
72	Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML). Leukemia Research, 2008, 32, 674-675.	0.8	16

APOSTOLOS TSAPAS

#	Article	IF	CITATIONS
73	Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors. Heart Failure Reviews, 2018, 23, 377-388.	3.9	16
74	Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis. Endocrine, 2017, 56, 485-494.	2.3	15
75	Non-dipping Status in Arterial Hypertension: An Overview. Current Vascular Pharmacology, 2014, 12, 527-536.	1.7	14
76	Eosinophilic pneumonia associated with heroin inhalation: a case report. Wiener Klinische Wochenschrift, 2008, 120, 178-180.	1.9	13
77	Effect of Leptin and Insulin Resistance on Properties of Human Monocytes in Lean and Obese Healthy Participants. Angiology, 2010, 61, 768-774.	1.8	13
78	Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications. Therapeutic Advances in Drug Safety, 2016, 7, 36-38.	2.4	13
79	Carvedilol for prevention of variceal bleeding: a systematic review and meta analysis. Annals of Gastroenterology, 2019, 32, 287-297.	0.6	13
80	Using N-of-1 Trials in Evidence-Based Clinical Practice. JAMA - Journal of the American Medical Association, 2009, 301, 1022.	7.4	12
81	Evaluation of the Greek TranQol: a novel questionnaire for measuring quality of life in transfusion-dependent thalassemia patients. Annals of Hematology, 2017, 96, 1937-1944.	1.8	11
82	Involvement of Signaling Molecules on Na+/H+ Exchanger-1 Activity in Human Monocytes. Open Cardiovascular Medicine Journal, 2010, 4, 181-188.	0.3	11
83	Association between BBS6/MKKS gene polymorphisms, obesity and metabolic syndrome in the Greek population. International Journal of Obesity, 2008, 32, 1618-1625.	3.4	10
84	Parotid gland oncocytoma: a case report. Cases Journal, 2009, 2, 6423.	0.4	10
85	Na+/H+exchanger-1: a link with atherogenesis?. Expert Opinion on Investigational Drugs, 2010, 19, 1545-1556.	4.1	10
86	Large- and Small-for-Gestational-Age Neonates Born by Women with Gestational Diabetes Mellitus Diagnosed by the New IADPSG Criteria: a Case-Control Study of 289 Patients and 1 108 Controls. Experimental and Clinical Endocrinology and Diabetes, 2013, 121, 262-265.	1.2	10
87	Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and metaâ€regression analysis. European Journal of Haematology, 2017, 98, 563-568.	2.2	10
88	Quality of Life in Greek Patients with Autoimmune Bullous Diseases Assessed with ABQOL and TABQOL Indexes. Acta Dermato-Venereologica, 2017, 97, 1145-1147.	1.3	10
89	Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 281-289.	1.9	10
90	GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. Diabetes Research and Clinical Practice, 2021, 177, 108921.	2.8	10

#	Article	IF	CITATIONS
91	Cariporide Counteracts Atherosclerosisâ€related Functions in Monocytes from Obese and Normal Individuals. Obesity, 2005, 13, 1588-1595.	4.0	9
92	Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis (Protocol). Systematic Reviews, 2012, 1, 61.	5.3	9
93	Decision aids for people with Type 2 diabetes mellitus: an effectiveness rapid review and metaâ€analysis. Diabetic Medicine, 2019, 36, 557-568.	2.3	9
94	Insulin sensitivity assessment with euglycemic insulin clamp in adult β-thalassaemia major patients. European Journal of Haematology, 2007, 79, 526-530.	2.2	8
95	Effect of Epinephrine and Insulin Resistance on Human Monocytes Obtained From Lean and Obese Healthy Participants: A Pilot Study. Angiology, 2011, 62, 38-45.	1.8	8
96	TIMER: A Clinical Study of Energy Restriction in Women with Gestational Diabetes Mellitus. Nutrients, 2021, 13, 2457.	4.1	8
97	Dose-related meta-analysis for Omega-3 fatty acids supplementation on major adverse cardiovascular events. Clinical Nutrition, 2022, 41, 923-930.	5.0	8
98	Patients' and Clinicians' Preferences on Outcomes and Medication Attributes for Type 2 Diabetes: a Mixed-Methods Study. Journal of General Internal Medicine, 2020, , 1.	2.6	7
99	Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus. American Journal of Hypertension, 2021, 34, 404-413.	2.0	7
100	Diabetic cardiomyopathy: a controversial entity. European Heart Journal, 2008, 29, 564-564.	2.2	6
101	Safety And Efficacy Of 4 Years Of Deferasirox Treatment For Sickle Cell Disease Patients. Hemoglobin, 2013, 37, 94-100.	0.8	6
102	Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2549-2557.	2.4	6
103	Add-on interventions for the prevention of recurrent Clostridioides Difficile infection: A systematic review and network meta-analysis. Anaerobe, 2021, 71, 102441.	2.1	6
104	Effect of Glucose and Insulin on Oxidized Low-Density Lipoprotein Phagocytosis by Human Monocytes: A Pilot Study. Angiology, 2011, 62, 163-166.	1.8	5
105	Is Deferasirox Implicated in Multiple Organ Failure in a Patient With Homozygous β-Thalassemia?. Angiology, 2011, 62, 346-348.	1.8	5
106	Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy. Core Evidence, 2017, Volume 12, 1-10.	4.7	5
107	Non-dipping pattern in early-stage diabetes: association with glycemic profile and hemodynamic parameters. Journal of Human Hypertension, 2022, 36, 805-810.	2.2	5
108	Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis. Endocrine, 2016, 54, 620-633.	2.3	4

APOSTOLOS TSAPAS

#	Article	IF	CITATIONS
109	Cyclical pressurized topical wound oxygen therapy increased healing of refractory diabetic foot ulcers. Annals of Internal Medicine, 2020, 172, JC27.	3.9	4
110	The relationship between early symptom severity, improvement and remission in first episode psychosis with jumping to conclusions. Schizophrenia Research, 2022, 240, 24-30.	2.0	4
111	Yersinia enterocolitica O:3 mesenteric lymphadenopathy in an apparently healthy adult. Netherlands Journal of Medicine, 2007, 65, 311-2.	0.5	4
112	Reporting completeness in abstracts of systematic reviews of diagnostic test accuracy studies in cardiovascular diseases is suboptimal. Hellenic Journal of Cardiology, 2022, 65, 25-34.	1.0	4
113	Monocyte attachment to laminin in diabetes mellitus. Cell Adhesion and Migration, 2009, 3, 155-159.	2.7	3
114	Review: Metformin does not increase risk for lactic acidosis in type 2 diabetes. Annals of Internal Medicine, 2010, 153, JC1.	3.9	3
115	Methodology for Quantifying Fasting Glucose Homeostasis in Type 2 Diabetes: Observed Variability and Lability. Journal of Diabetes Science and Technology, 2013, 7, 640-645.	2.2	3
116	Some glucose-lowering drugs reduce risk for major adverse cardiac events. Annals of Internal Medicine, 2020, 173, JC9.	3.9	3
117	Glycemia and cardiovascular risk: challenging evidence based medicine. Hippokratia, 2011, 15, 199-204.	0.3	3
118	Medical student recognition of benign anorectal conditions: the effect of attending the outpatient colorectal clinic. BMC Surgery, 2014, 14, 95.	1.3	2
119	Canagliflozin for Type 2 diabetes: an up-to-date evidence summary. Diabetes Management, 2015, 5, 119-125.	0.5	2
120	Premixed insulin regimens for type 2 diabetes. Endocrine, 2016, 51, 387-389.	2.3	2
121	Meta-analysis of artificial pancreas trials: methodological considerations. Lancet Diabetes and Endocrinology,the, 2017, 5, 685.	11.4	2
122	Budget Impact Analysis of Empagliflozin For The Treatment of Patients With Type 2 Diabetes Mellitus At Increased Cardiovascular Risk In Greece. Value in Health, 2017, 20, A476.	0.3	2
123	Septicemia caused by Oligella urethralis in a patient with end-stage cancer. Clinical Microbiology Newsletter, 2006, 28, 30-31.	0.7	1
124	Authors' reply to Scheffel and Schaan. BMJ, The, 2012, 344, e2922-e2922.	6.0	1
125	Review: Sodium–glucose cotransporter 2 inhibitors reduce HbA _{1c} and weight but increase infections. Annals of Internal Medicine, 2014, 160, JC10.	3.9	1
126	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. Annals of Internal Medicine, 2015, 163, 241.	3.9	1

#	Article	IF	CITATIONS
127	In type 2 diabetes, weekly semaglutide reduced HbA _{1c} and increased weight loss more than weekly exenatide ER. Annals of Internal Medicine, 2018, 168, JC46.	3.9	1
128	Omega-3 Supplementation And Cardiovascular Disease: Meta-Analysis With Trial Sequential Analysis. Atherosclerosis, 2019, 287, e284.	0.8	1
129	SO036THE EFFECT OF DAPAGLIFLOZIN ON AMBULATORY AORTIC BLOOD PRESSURE AND ARTERIAL STIFFNESS PARAMETERS IN PATIENTS WITH TYPE-2 DIABETES MELLITUS: A DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
130	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. Annals of Internal Medicine, 2021, 174, 141.	3.9	1
131	KDIGO made 12 recommendations for managing diabetes with CKD. Annals of Internal Medicine, 2021, 174, JC26.	3.9	1
132	Parotid gland oncocytoma: a case report. Cases Journal, 2009, 2, .	0.4	1
133	Insulin secretagogues were associated with increased mortality compared with metformin in type 2 diabetes. Annals of Internal Medicine, 2012, 156, JC1.	3.9	1
134	Investigating the role of Natural Killer T-cells in Gram negative infections of patients with type 2 diabetes mellitus. Hippokratia, 2015, 19, 231-4.	0.3	1
135	Hemosiderosis and diabetes mellitus in an untransfused patient with hemoglobin H disease and H63D homozygous hereditary hemochromatosis. Diabetes Research and Clinical Practice, 2007, 76, 468-469.	2.8	0
136	PO014 In vitro growth modulation by L-ascorbic acid (L-AA) of colony forming cells from bone marrow of patients with refractory anemia (RA). Leukemia Research, 2007, 31, S135-S136.	0.8	0
137	Intensive insulin therapy reduced long-term risk for incident hypertension in type 1 diabetes. Annals of Internal Medicine, 2009, 150, JC2.	3.9	0
138	Leptin, Adiponectin, and Insulin Resistance. Angiology, 2011, 62, 349-349.	1.8	0
139	Safety of deferasirox in sickle cell disease patients with coâ€existing liver impairment. British Journal of Haematology, 2012, 157, 505-506.	2.5	0
140	Sodium-Glucose Cotransporter 2 Inhibition and Cardiovascular Risk. Current Cardiovascular Risk Reports, 2016, 10, 1.	2.0	0
141	Cost-Effectiveness of Empagliflozin For The Treatment of Patients With Type 2 Diabetes Mellitus At Increased Cardiovascular Risk In Greece. Value in Health, 2017, 20, A479.	0.3	0
142	P662 Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Journal of Crohn's and Colitis, 2017, 11, S418-S419.	1.3	0
143	P670 Comparative efficacy on steroid-free remission of pharmacological therapies for moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis. Journal of Crohn's and Colitis, 2018, 12, S449-S450.	1.3	0
144	Decreased cortisol response to lowâ€dose Synacthen test in pediatric patients with type 1 diabetes. Journal of Diabetes, 2019, 11, 773-774.	1.8	0

#	Article	IF	CITATIONS
145	In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors. Annals of Internal Medicine, 2020, 173, JC70.	3.9	0
146	P1026THE EFFECT OF DAPAGLIFLOZIN ON 24-HOUR BLOOD PRESSURE IN PATIENTS WITH TYPE-2 DIABETES MELLITUS: A DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
147	Fluid volume regulation in patients with heart failure. Lancet Diabetes and Endocrinology,the, 2021, 9, 257-258.	11.4	0
148	MO642DAPAGLIFLOZIN HAS NO IMPACT ON SHORT-TERM BLOOD PRESSURE VARIABILITY IN PATIENTS WITH TYPE-2 DIABETES MELLITUS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
149	Parotid gland oncocytoma: a case report. Cases Journal, 2009, 2, .	0.4	0